Introduction
============

The complex biomechanical features of hyaline cartilage are difficult to reproduce. An articular chondral surface has a peculiar ultrastructure, with chondrocytes sparsely distributed and minimal cell-to-cell contact, interacting in a surrounding matrix characterised by a complex framework of collagen, aggrecan and fluid.^[@r1]-[@r3]^Treatment options aimed at the recruitment of potential cartilage precursors allowing stem cell migration from the marrow cavity to the fibrin clot of the defect, such as abrasion, drilling and microfracture, produce predominantly type I collagen, fibrocytes and an unorganised matrix.^[@r4]^ This fibrous repair tissue lacks the biomechanical and viscoelastic characteristics of the original hyaline cartilage, and does not lead to durable results.^[@r5]^ Techniques aiming at transferring autologous osteochondral units from less weight-bearing areas to repair the lesion with a healthy tissue allow a valid articular surface to be reconstructed with good coverage of the defect and graft stability in small lesions.^[@r6]^ Donor site availability and technical difficulties are critical aspects that limit this approach for medium to large surfaces. An alternative option is the use of homologous osteochondral grafts, but there are concerns regarding low availability, the difficulty of preserving and managing fresh allografts and the risk of disease transmission.^[@r7],[@r8]^ These concerns have reduced the indication of this procedure to large osteochondral lesions in young patients with high functional requirements, who are otherwise doomed to poor clinical outcome.^[@r9]^

The pioneers of this ambitious treatment approach developed and introduced the autologous chondrocyte implantation (ACI) technique in Sweden showing firstly in 1994 satisfactory results for the treatment of isolated femoral condyle lesions.^[@r10]^ Several studies followed and claimed both the production of a hyaline-like articular surface and a good outcome at medium to long-term follow-up: Vasiliadis et al^[@r11]^ used MRI to show good tissue quality despite the evidence of some osteophytes, cysts, and oedema, and Peterson et al^[@r12]^ reported good results in 224 cases at 13 years with 92% of patients satisfied (n = 206). However, these good results have to be weighed against several problems. From a surgical point of view, the standard ACI procedure presents various limitations related to the complexity and morbidity of the technique, including the difficulty in handling a delicate liquid suspension of chondrocytes, the need to make a hermetic periosteum seal using sutures to avoid cell leakage, the requirement of a second open surgery with a subsequent long rehabilitation period, and a high rate of complications and re-operation due to flap hypertrophy, arthrofibrosis and joint stiffness.^[@r13]^ From a biological point of view, critical aspects are the maintenance of the chondrocyte phenotype during the prolonged monolayer culture and the risk of a non-homogeneous distribution of the liquid cell suspension in the lesion area.^[@r13]^ Tissue engineering has been developed to address most of these problems, leading to the introduction into clinical practice ten years ago of the so-called matrix-assisted autologous chondrocyte transplantation (MACT) procedures.^[@r14]^

The aim of this systematic review is to document and analyse the available evidence in the literature on the results obtained in clinical practice by MACT techniques to address chondral and osteochondral knee lesions.

Materials and Methods
=====================

All studies on MACT procedures published in English were identified. Two reviewers performed a search of the Medline database from 2000 to March 2012, using the terms "cartilage regeneration", "autologous chondrocyte transplantation", "autologous chondrocyte implantation", "second / third generation ACI", "matrix-assisted chondrocyte implantation", "scaffold-based repair" and "osteochondral repair". Studies were included in our systematic review if they fulfilled the following criteria: 1) level I-IV evidence addressing the areas of interest outlined above; 2) measures of functional or clinical outcome; 3) outcome related to knee cartilage lesions. Citations from relevant studies, as well as any relevant articles captured by the search, were also examined to determine if they were suitable for inclusion. Studies not fulfilling these criteria were excluded.

Results
=======

The search identified 187 articles. The number of articles per year increased progressively from 2000, as depicted in Figure 1. Including those with short follow-up, a total of 51 articles fulfilled the inclusion criteria: there were three randomised studies, ten comparative studies, 33 case series, and five case reports. All studies are reported and summarised in Table I^[@r15]-[@r66]^; those reporting clinical results at a minimum follow-up of two years are described in more detail in the following paragraphs.
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###### 

Details of the 51 articles focusing on clinical results of matrix assisted autologous chondrocyte implantation (MACI) procedures

  **Author/s**                 **Procedure**          **Patients (n)^\*^**           **Mean size of lesion (cm^2^) (range)**   **Mean follow-up (yrs)**             **Study level^†^**
  ---------------------------- ---------------------- ------------------------------ ----------------------------------------- ------------------------------------ --------------------
                                                                                                                                                                    
  **2003**                                                                                                                                                          
  Marcacci et al^[@r54]^       Hyalograft C           20                             2.9                                       1                                    Prospective study
  Cherubino et al^[@r55]^      MACI                   13                             3.5                                       6.5 mths (2 to 15)                   Case series
  Pavesio et al^[@r56]^        Hyalograft C           67                             \-                                        17.5 mths                            Cohort study
  **2004**                                                                                                                                                          
  Ronga et al^[@r57]^          MACI                     1                            2                                         1                                    Case report
  Marlovits et al^[@r58]^      MACI                   16                             4.7 (2.6 to 10.9)                         3.1 mths                             Case series
  **2005**                                                                                                                                                          
  Bartlett et al^[@r59]^       MACI                     5                            2.2 to 8.0                                1                                    Prospective study
  Bartlett et al^[@r60]^       MACI                   44 ACI-C/47 MACI               6.1                                       1                                    RCT
  Marcacci et al^[@r24]^       Hyalograft C           141                            3.5                                       38 mths                              Case series
  **2006**                                                                                                                                                          
  Nehrer et al^[@r25]^         Hyalograft C           36                             1.5 to 8                                  3                                    Case series
  Behrens et al^[@r15]^        MACI                   11                             1.5 to 17.7                               5                                    Case series
  Ronga et al^[@r16]^          MACI                     1                            5                                         2                                    Case report
  Gobbi et al^[@r26]^          Hyalograft C           32                             4.7                                       2                                    Case series
  **2007**                                                                                                                                                          
  Marcacci et al^[@r28]^       Hyalograft C           70                             2.4                                       2 to 4                               Case series
  Manfredini et al^[@r61]^     Hyalograft C           17 ACI/10 Hyalograft C         \-                                        1                                    Comparative study
  Adachi et al^[@r51]^         Atelocollagen            1                            5 and 3                                   2                                    Case report
  Ossendorf et al^[@r38]^      Bioseed C              40                             4.6                                       2                                    Case series
  **2008**                                                                                                                                                          
  Ebert et al^[@r62]^          MACI                   62                             \-                                        2                                    RCT
  Selmi et al^[@r48]^          Cartipatch             17                             3                                         2                                    Case series
  Ferruzzi et al^[@r30]^       Hyalograft C           48 ACI I gen/50 Hyalograft C   6.4 / 5.9                                 5                                    Comparative study
  **2009**                                                                                                                                                          
  Gigante et al^[@r18]^        MACI                   12                             4                                         3                                    Case series
  Kon et al^[@r5]^             Hyalograft C           40 Hyalograft C/40 MFX         2.2 / 2.5                                 5                                    Comparative study
  Kreuz et al^[@r39]^          Bioseed C              19                             4                                         4                                    Case series
  Crawford et al^[@r43]^       Neocart                  8                            2.2                                       2                                    Case series
  Gobbi et al^[@r27]^          Hyalograft C           34                             4.4                                       5                                    Case series
  Salzmann et al^[@r17]^       MACI                     9 OCT/9 MACI                 2.3 / 6.3                                 41 mths/42 mths                      Comparative study
  Wondrasch et al^[@r46]^      Hyalograft C / CaReS   31                             4.8                                       2                                    Case series
  Nehrer et al^[@r29]^         Hyalograft C           42 arthrotomy/11 arthroscopy   4.4                                       2 to 7                               Case series
  Tohyama et al^[@r52]^        Atelocollagen          27                             3.2                                       2                                    Case series
  Vilchez et al^[@r63]^        Chondrograft           15                             1.5 to 8                                  1                                    Prospective study
  **2010**                                                                                                                                                          
  Della Villa et al^[@r33]^    Hyalograft C           31 athletes/34 non-athletes    2.2 / 2.3                                 57 mths/52 mths                      Comparative study
  Welsch et al^[@r45]^         Hyalograft C / CaReS   10 CaReS/10 Hyalograft C       4.6 / 4.9                                 2                                    Comparative study
  Basad et al^[@r19]^          MACI                   33 MACI/15 MFX                 \> 4                                      2                                    Randomised study
  Kim et al^[@r50]^            Chondron               30                             5.8                                       2                                    Case series
  Kon et al^[@r31]^            Hyalograft C           50                             2.5                                       5                                    Case series
  Zeifang et al^[@r42]^        Bioseed C              11 Bioseed C/10 ACI I gen      4.3 / 4.1                                 2                                    Randomised study
  Choi et al^[@r49]^           Chondron               40                             5.2                                       Minimum 2                            Case series
  Clar et al^[@r34]^           Hyalograft C             1                            14                                        5.5                                  Case report
  Erggelet et al^[@r41]^       Bioseed C              40 Bioseed C/42 ACI I gen      2 to 17.5 / 2 to 15                       2                                    Comparative study
  **2011**                                                                                                                                                          
  Ebert et al^[@r20]^          MACI                   35                             3.0                                       5                                    Case series
  Macmull et al^[@r64]^        MACI                   24 ACI/7 MACI                  0.96 to 15.7                              66.3 mths                            Comparative study
  Bauer et al^[@r22]^          MACI                   18                             6                                         5                                    Case series
  Kon et al^[@r32]^            Hyalograft C           22 Hyalograft C/39 MACI        2.6 / 3.1                                 5.1/4.8                              Comparative study
  Kreuz et al^[@r40]^          Bioseed C              52                             4.8                                       4                                    Case series
  Enea et al^[@r65]^           MACI                   30                             5.0                                       15 mths                              Case series
  Schneider et al^[@r47]^      CaReS                  116                            5.4                                       12 to 60 mths                        Case series
  Filardo et al^[@r35]^        Hyalograft C           32                             3                                         6                                    Case series
  Filardo et al^[@r36]^        Hyalograft C           58                             2.3                                       6                                    Case series
  Kon et al^[@r53]^            Hyalograft C           21 Hyalograft C/20 MFX         2                                         7.5                                  Comparative study
  Filardo et al^[@r37]^        Hyalograft C           62                             2.5                                       7                                    Case series
  **2012**                                                                                                                                                          
  Ventura et al^[@r23]^        MACI                   53                             4.3                                       27 mths (n = 53)/59 mths (n = 17 )   Case series
  Macmull et al^[@r21]^        MACI                   25 ACI/23 MACI                 4.7                                       40 mths                              Comparative study
  Panagopoulos et al^[@r44]^   Novocart               11 ACI/8 MACI                  6.5                                       37.5 mths                            Comparative study
  Könst et al^[@r66]^          Gel MACI                 9                            7.1                                       9 mths                               Case series
                                                                                                                                                                    

\* (M)ACI-C, (matrix) autologous chondrocyte implantation-collagen membrane; MFX, microfractures; CaReS, Cartilage Repair System (Ars Arthro Technology) † RCT, randomised controlled trial

Matrix autologous chondrocyte implantation (MACI)
-------------------------------------------------

The first autologous chondrocyte transplantation using a porcine collagen type I/III membrane (Chondro-Gide; Geistlich Biomaterials, Wolhusen, Switzerland) was performed in 1998.^[@r67]^ As in every MACT procedure, the surgical technique involves two surgical steps: harvesting articular cartilage from a non-weight-bearing area and, after culturing cells for four weeks and then seeding and culturing for the remaining three days on the rough side of the collagen matrix, implantation of the bioengineered tissue into the lesion (MACI; Verigen Transplantation Service, Copenhagen, Denmark). In 2006 Behrens et al^[@r15]^ published a five-year prospective study, reporting that eight of 11 patients rated the function of their knee as much better or better than before. In the same year Ronga et al^[@r16]^ reported the successful treatment of a complex knee ligament, meniscal and chondral lesion in a 40-year-old sportsman at two years' follow-up. Normal biomechanics of the joint were restored by performing a collagen meniscus implant and anterior cruciate ligament reconstruction during the first step, and after six months a 5 cm^2^ chondral lesion was treated with the second-step MACI procedure. Salzmann et al^[@r17]^ confirmed these good results in a comparative study, in which nine patients treated with MACI obtained a significant clinical improvement with results higher than those obtained in a matching group of patients who underwent osteochondral autograft transplantation. Gigante et al^[@r18]^ focused on a specific patient population affected by patellar lesion and treated with patellofemoral distal realignment and cartilage reconstruction: all 12 patients (14 knees) presented a significant improvement in all scales. Basad et al^[@r19]^ performed a randomised trial comparing MACI and microfracture for the treatment of lesions \> 4 cm^2^: at two years, MACI demonstrated significantly higher and more stable results over time. Ebert et al^[@r20]^ evaluated 35 patients at five years, showing a clinical and MRI improvement up to two years and then stable results over time, with 35 patients (86%) satisfied with the results. More recently, Macmull et al^[@r21]^ evaluated the treatment of symptomatic chondromalacia patellae in 23 patients evaluated at a follow-up of 40 months: results were satisfactory and better than those obtained in a comparative ACI group. Bauer et al^[@r22]^combined MACI and neutralising high tibial osteotomy in patients with medial knee osteoarthritis and varus deformity, documenting good clinical and MRI results initially but a significant decline at five years. Finally, Ventura et al^[@r23]^ documented good results in 53 patients at two years, confirmed by the 17 patients evaluated at five years of follow-up, with improvements in function and pain and complete integration of the graft within the surrounding native cartilage in 15 patients (88%) at five years.

Hyalograft C
------------

Hyaluronic acid, another widely represented cartilage matrix element, is the main component of Hyalograft C, introduced into clinical practice in 1999.^[@r68]^ This scaffold is entirely based on the benzylic ester of hyaluronic acid (HYAFF 11; Fidia Advanced Biopolymers Laboratories, Padova, Italy) and consists of a network of 20 µm thick fibers with interstices of variable sizes. The features of this device allowed the development of an arthroscopic surgical technique,^[@r68]^ and in 2005 Marcacci et al^[@r24]^ reported the clinical results of a multicentre study on 141 patients evaluated at a minimum follow-up of two years. A mean three-year follow-up evaluation showed 129 patients (91.5%) had subjectively improved results, and cartilage repair was graded arthroscopically as normal or nearly normal in 53 of 55 knees (96.4%) that underwent second-look arthroscopy. Moreover, 12 of 22 second-look biopsies were judged as hyaline-like, and a low complication rate was recorded. In the same period, Nehrer et al^[@r25]^ confirmed the good short-term results in a group of 36 patients followed for three years, and Gobbi et al^[@r26]^ reported a positive outcome at two years in 32 patellofemoral full-thickness chondral defects. The same group of patients were described at five years,^[@r27]^ showing a worsening with respect to the previous study, but still good clinical and histological results. A medium-term follow-up evaluation was also performed by Marcacci et al^[@r28]^ and Nehrer et al^[@r29]^ who confirmed the significant clinical improvement with stable results over time. Ferruzzi et al^[@r30]^ treated 50 patients affected by osteochondritis dissecans (OCD) and traumatic lesions, and showed stable clinical results at minimum five years' follow-up and a well-integrated cartilage tissue in 93% of the patients at the final MRI evaluation. Moreover, they also compared them with a group of patients treated with first-generation ACI and showed a similar healing potential but with fewer complications and a more rapid recovery when the arthroscopic MACT procedure was used.^[@r30]^ Kon et al^[@r31]^ followed a group of patients clinically and with MRI for five years and reported durability of the good clinical results obtained and a correlation between imaging and clinical findings. These results were also confirmed in a demanding patient population of high-level soccer players evaluated at 7.5 years: whereas microfracture allowed a faster recovery but presented a clinical deterioration over time, arthroscopic Hyalograft C delayed the return to competition but offered more durable clinical results.^[@r32]^Della Villa et al^[@r33]^ focused on the post-operative phase by evaluating highly competitive athletes, and demonstrated that an intensive rehabilitation may safely allow a faster return to competition and also positively influences the clinical outcome at medium-term follow-up. Clar et al^[@r34]^ reported the use of hyaluronic-based MACT as a salvage treatment for a 14 cm^2^ defect in a 17.5-year-old girl, due to previous steroid-induced osteonecrosis: after treatment, formation of a solid cartilage layer was observed on MRI and a continuous clinical improvement registered up to 5.5 years. Kon et al^[@r69]^ analysed and compared results obtained using arthroscopic Hyalograft C implantation or the mini-open MACI technique^[@r15]^ for the treatment of cartilage lesions in 61 patients \> 40 years of age with no clear signs of osteoarthritis. Results were inferior compared with those previously found for younger populations, with a higher rate of failure, but a significant clinical improvement was still found at five years.^[@r69]^ In fact, this group of patients also benefited in most cases from both cartilage regenerative procedures, with the only difference being a faster recovery when the arthroscopic approach was used. Finally, in 2011 Filardo et al^[@r35]-[@r37]^ confirmed the good results obtained with this scaffold up to seven years of follow-up, documenting overall good and stable results over time but a lower outcome in case of degenerative lesions.

Bioseed
-------

Bioseed C (BioTissue Technologies GmbH, Freiburg, Germany) scaffold is composed of fibrin, polyglicolic/polilactic acid and polydioxanone. It is a tissue-engineered graft that combines autologous chondrocytes, embedded in fibrin, with a 2 mm thick porous gel-like matrix in a bioresorbable polymer scaffold, and has been applied in clinical practice since 2001.^[@r38]^ This biomaterial can be implanted by open or arthroscopic procedure and presents a particular type of fixation: after careful debridement of the defective cartilage to a rectangular shape, the graft is fitted to the size of the defect and a strong fixation is obtained by arming the corners with resorbable threads, anchored transosseously to each corner, thus ensuring secure fixation of the graft even in defects without intact surrounding cartilage. Ossendorf et al^[@r38]^ reported in 2007 clinical results at two years in a group of 40 patients affected by degenerative defects, and showed good integration of the graft, formation of a cartilaginous repair tissue and a significant clinical improvement even in the more challenging osteo-arthritic lesions. Kreuz et al^[@r39]^ then confirmed the good results obtained in 19 patients of the same group analysed at four years, and a further evaluation of 52 patients also showed clinical improvement and moderate-to-complete filling at the MRI in the majority of the patients, even if a persisting strength deficit was found in the treated knee.^[@r40]^

Finally, a similar significant improvement to that achieved with the original ACI periosteum-cover technique was found independently by Erggelet et al^[@r41]^ in a retrospective comparative study and by Zeifang et al^[@r42]^ in a randomised clinical trial.

More recently, among the many scaffolds developed, a few other biomaterials have been introduced into clinical practice with a minimum follow-up of two years.

Neocart
-------

NeoCart (Histogenics Corporation, Waltham, Massachusetts) consists of a three-dimensional (3D) type I collagen scaffold seeded with autologous chondrocytes and then undergoing development in a bioreactor.^[@r43]^ The resulting product is a viable proteoglycan- and glycosaminoglycan-rich tissue-like implant, which is surgically fixed to the damaged area with CT3 bioadhesive (Histogenics). Crawford et al^[@r43]^ reported a good clinical outcome at two years of follow-up in eight patients, describing good implant integration, defect fill, as well as progressive maturation and more organised cartilage formation.

Novocart
--------

Novocart 3D (B. Braun-Tetec, Reutlingen, Germany) comprises autologous chondrocytes embedded in a 3D collagen-chondroitin sulfate scaffold. Results were recently reported by Panagopoulos, van Niekerk and Triantafillopoulos,^[@r44]^ who evaluated a cohort of either professional soldiers or athletes with large defects after classic ACI with periosteal flap in 11 cases and Novocart 3D in eight cases. At a minimum of two years, despite the overall improvement, results obtained in this demanding cohort with complex lesions were poor, with only six patients (32%) returning to previous athletic performances. A trend toward better results for Novocart 3D was found in comparison with classic ACI, but without reaching statistical significance.

CaReS
-----

CaReS(Ars Arthro, Esslingen, Germany) consists of autologous chondrocytes seeded on 3D type-I collagen gel. The cells are isolated, mixed with collagen, and after complete gelling and two weeks of culturing, the chondrocyte-loaded gel is available for transplantation. Welsch et al^[@r45]^ evaluated two bioregenerative approaches: ten patients underwent CaReS implantation and were compared with ten patients treated with Hyalograft C, matched according to lesion size, site and age of patients. Although the clinical outcome at two years was comparable between the two groups, MRI analysis revealed better surface of the repair tissue in the CaReSgroup.^[@r45]^ Wondrasch et al^[@r46]^ applied CaReS or Hyalograft Cin 31 patients, documenting an overall significant improvement at two years. The patients were randomised into either an accelerated or delayed weight-bearing protocol, which demonstrated that early weight-bearing was associated with a higher prevalence of bone marrow oedema after six months, but with no effect on clinical outcome.^[@r46]^ More recently, Schneider et al^[@r47]^ published the results of a multicentre study in which a wide population of 116 patients was evaluated at a follow-up from 12 to 60 months: overall good results were reported, with a continuous improvement towards best results at the last follow-up, regardless of lesion size, site and number of defects, whereas a greater improvement was documented in the OCD group.

Cartipatch
----------

Cartipatch (TBF Tissue Engineering, Mions, France) is an autologous chondrocyte implant on a vegetal hydrogel composed of agarose and alginate. This hydrogel is mixed with isolated autologous cell suspension and can be modulated at 37°C into complex-shaped implants that solidify at approximately 25°C. Alginate provides matrix elasticity, making it easy to handle. Selmi et al^[@r48]^ investigated the clinical, radiological, arthroscopic and histological outcome at a minimum follow-up of two years for the treatment of chondral and osteochondral defects. Clinically, all 17 patients improved markedly, especially those with lesions \> 3 cm^2^. Good MRI findings, arthroscopic appearance and predominantly hyaline cartilage were found in eight of 13 biopsies performed (62%).

Chondron
--------

Another gel-type autologous chondrocyte (Chondron; Sewon Cellontech Co. Ltd, Seoul, Korea) implantation has been used by Choi et al.^[@r49]^ This procedure involves the injection of cultured chondrocytes mixed with fibrin (1:1) into the defect area previously prepared with debridement and multiple holes. In a multicentre study they evaluated 40 patients with follow-up \> two years, showing the safety and effectiveness of this method. Fibrin gel can provide a 3D scaffold with the advantages of technical simplicity and minimal invasiveness. Kim et al^[@r50]^ have also shown satisfactory results in 30 patients, with significant clinical improvements, good MRI findings and nearly normal arthroscopic appearance in most patients at two years.

Atelocollagen gel
-----------------

Autologous chondrocytes cultured on atelocollagen gel have been also documented. Adachi et al^[@r51]^ first reported a complex case in which corticosteroid-induced osteonecrosis at both condyles of the knee was treated with hydroxyapatite with interconnected pores (IP-CHA) and atelocollagen gel (3% type I collagen; Koken, Tokyo, Japan) used as a scaffold for bone-marrow expanded cells and cultured chondrocytes, and to regenerate both osseous and chondral tissues, respectively. A synovial flap was sutured to cover the lesion and secure the osteochondral implants. Despite the unremarkable arthroscopic findings at a one-year follow-up, MRI and clinical results showed a successful outcome at two years. Tohyama et al^[@r52]^ conducted a multicentre study on 27 patients to determine the usefulness of the atelocollagen-associated chondrocyte implantation for the repair of chondral knee defects. The first-generation ACI periosteal flap technique was used to host and protect the chondrocyte-atelocollagen gel. Both clinical and arthroscopic outcomes were positive, with a marked improvement and 23 knees (92%) presented normal or nearly normal arthroscopic appearance.

Discussion
==========

Research in bioengineering offers new technologies and new surgical treatment options for cartilage lesions. The use of 3D structures for cell growth has been shown to allow the maintenance of a chondrocyte differentiated phenotype^[@r70]^ and to overcome most of the biological and surgical concerns raised by the first-generation methods.^[@r13],[@r14],[@r71]^ Thus, the interest in this scaffold-based cartilage regenerative approach is constantly growing, as shown by the increasing number of publications every year that focus on this topic (Fig. 1).

The rationale of using a scaffold is to have a 3D biodegradable structure for the *in vitro* growth of living cells and their subsequent implantation. An ideal scaffold should mimic the biology, architecture and structural properties of the native tissue, thus facilitating cell infiltration, attachment, proliferation and differentiation. Other important properties include biocompatibility and biodegradability through safe biochemical pathways at suitable time intervals to support the first phases of tissue formation and then the gradual replacement by the regenerating tissue.

Following these principles, many scaffolds have been developed and, as reported in this systematic review, introduced in the clinical practice with promising results. As polymers can be designed to have a wide range of properties and are easily modified depending on the biological/surgical strategy, many more are being developed. Several other natural and synthetic scaffolds for cartilage regeneration are under investigation and will be available in clinical practice.^[@r13],[@r14],[@r71]^ In particular, hydrogels have recently been developed as an attractive evolution of cartilage tissue engineering. Another important source of innovation comes from photopolymerisation: liquid or gel scaffolds can be injected into the site of cartilage injury, thus requiring a less invasive procedure, and then polymerised by exposure to ultraviolet light. It is also possible to encapsulate cells within the gels, thus obtaining a scaffold with uniformly distributed cells, offering both surgical and biological potential advantages.^[@r48]^

MACT was introduced into clinical practice in Europe between 1998 and 1999 and a considerable number of clinical studies have been published. However, since introduction into clinical practice is recent, it is difficult to have a long-term follow-up, and most of the papers report case series; up to now only ten non-randomised and three randomised controlled studies have been published, and the few comparative studies available are not conclusive.

Moreover, in the United States the Food and Drug Administration has not yet approved MACT, but different alternative solutions are being developed, avoiding manipulation of cells and regulatory obstacles. In fact, there is an increasing awareness that the role of scaffolds is not only to deliver cells to enhance tissue regeneration, and the use of cell-free scaffolds has been proposed and is gaining popularity. Some scaffolds may have a potential themselves to promote chondral or osteochondral regeneration by exploiting the self-regenerative potential of the body.^[@r53],[@r72]^ One-step cell-free approaches have been developed to avoid the problems related to the *ex vivo* chondrocyte culture and expansion in a scaffold, with marked advantages both from the surgical and economic points of view.

In fact, an ideal graft would be an off-the-shelf product. The possibility of a cell-free implant that is 'smart' enough to provide the joint with the appropriate stimuli to induce orderly and durable tissue regeneration is an attractive prospect, and new biomaterials and surgical strategies have been recently proposed to induce *in situ* cartilage regeneration after direct transplantation onto the defect site.

Finally, the increasing awareness on the role of the subchondral bone has led to the development of some new biphasic products: the bilayer structure allows the entire osteochondral unit to be treated, which is important in particular in cases of large chondral or osteochondral articular defects, reproducing the different biological and functional requirements for guiding the growth of both bone and cartilage tissues.^[@r53],[@r73]^

Promising results have been reported with all of these procedures,^[@r27],[@r53],[@r74],[@r75]^ but the properties of the healthy cartilage tissue are still unmatched by any available substitute. Moreover, despite the thousands of patients treated and the published studies suggesting good clinical results, at the present time there is no agreement about the effective superiority of the regenerative approach over the others, and both results and indications remain controversial. One explanation of the contradictory and inconclusive findings in the literature might be that regenerative procedures may lead to a hyaline-like tissue through a remodeling process, thus leading to superior clinical results only detectable at two to three years of follow-up.^[@r76]^ Unfortunately, due to the recent development of these techniques, only a few studies report medium to long-term results,^[@r13],[@r14]^ and up to now only a few comparative trials have been performed. Thus, medium to long-term comparative studies are mandatory to confirm the positive findings reported and to determine the real potential of the bioengineered approach with respect to the more traditional and less ambitious procedures.

Conclusions
-----------

MACT procedures have been reported in the literature in the last decade with promising results, and the growing interest on this scaffold based regenerative approach is confirmed by the growing number of publications documented in this review. Different types of scaffolds have been applied in the clinical practice and shown a good outcome at short and medium-term follow-up, but well-designed studies are lacking. Systematic long-term evaluation of these techniques and randomised controlled studies are necessary to confirm the potential of this tissue-engineered approach, especially compared with the available traditional treatments.
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